Results 51 to 60 of about 1,671,005 (331)

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

Development and evaluation of a hot-melt coating technique for enteric coating [PDF]

Brazilian Journal of Pharmaceutical Sciences, 2012
Conventional enteric coating requires the use of organic based polymers which are equally hazardous to the environment and operating personnel. Hot-melt coating avoids the use of solvents and is a safer and time-saving process. The present study was designed to assess the efficacy of hot-melt coating (HMC) as an enteric coating technique.
Patil, Arun Trambak, Khobragade, Deepak Shamrao, Chafle, Sandip Annaji, Ujjainkar, Amol Prasadrao, Umathe, Sudhir Niranjanrao, Lakhotia, Champalal Laxminarayan   +5 more
openaire   +4 more sources

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Preparation and optimization of various parameters of enteric coated pellets using the Taguchi L9 orthogonal array design and their characterization

Acta Pharmaceutica Sinica B, 2011
Duloxetine hydrochloride enteric coated pellets were formulated using fluidized bed. Three separate layers, the drug layer, the barrier layer, and the enteric layer, were coated onto the inert core pellets.
D. Shravani, P.K. Lakshmi, J. Balasubramaniam   +2 more
doaj   +1 more source

Kinetics of Release from Enteric-Coated Tablets [PDF]

Pharmaceutical Research, 1988
Controlled and localized release of drugs in the intestine can be achieved by enteric coating. The design of enteric-coated tablets has so far remained empirical, in part because of the lack of a quantitative description of the drug release kinetics. In this paper, a mathematical model is presented that describes the dissolution of the polymer coating ...
Palsson, Bernhard Ø, Dressman, Jennifer B., Donohoe, Bruce, Ozturk, Sadettin S.   +3 more
openaire   +4 more sources

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Enteric coating of granules containing the probiotic Lactobacillus acidophilus

Acta Pharmaceutica, 2014
In the present study, a capsule formulation composed of enteric coated granules of Lactobacillus acidophilus ATCC 4962 was developed using Eudragit L30D-55 as enteric polymer.
Pyar Hassan, Peh Kok-Khiang
doaj   +1 more source

Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management

Molecular Oncology, EarlyView.
DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez, Asieh Naderi, Kim‐Tuyen Huynh‐Dam, Vitali Sikirzhytski, Ioulia Chatzistamou, Hippokratis Kiaris   +5 more
wiley   +1 more source

Characterization of ribosome heterogeneity during endothelial to hematopoietic transition

FEBS Open Bio, EarlyView.
The panorama of ribosome heterogeneity during embryonic hematopoiesis has not yet been portrayed. In this study, utilizing dual‐omics data, the heterogenous dynamic of ribosome during endothelial‐to‐hematopoietic transition has been systemically described. Moreover, stage‐specific upregulation and peripheral localization of RPL27 and RACK1 in hemogenic
Xitong Tian, Di Liu, Bing Liu, Yu Lan, Jie Zhou   +4 more
wiley   +1 more source

Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects

Clinical and Translational Science, 2023
Bersiporocin, a novel first‐in‐class prolyl‐tRNA synthetase (PRS) inhibitor currently under clinical development, was shown to exert an antifibrotic effect through the downregulation of collagen synthesis in various pulmonary fibrosis models.
Min Young Park, Sungyeun Bae, Jung A Heo, Mihee Park, YuKyung Kim, Jumi Han, In‐Jin Jang, Kyung‐Sang Yu, Jaeseong Oh   +8 more
doaj   +1 more source